Senior Care Pharmacist最新文献_第9页

Heart Failure in Older People Part 2: Guideline-Directed Medical Therapy. 老年人心力衰竭第二部分：指南指导下的药物治疗。

Senior Care Pharmacist Pub Date : 2024-10-01 DOI: 10.4140/TCP.n.2024.360

Elizabeth Pogge, Stephanie Sibicky

引用次数: 0

It Takes a Village…. It Takes a Village....

Senior Care Pharmacist Pub Date : 2024-08-01 DOI: 10.4140/TCP.n.2024.283

Gauri Godbole

引用次数: 0

Does the Pharmacy Profession View the Full Picture of Cognitive Disorders? 药学专业是否了解认知障碍的全貌？

Senior Care Pharmacist Pub Date : 2024-08-01 DOI: 10.4140/TCP.n.2024.281

Chris Alderman

引用次数: 0

Impact of a Delirium Protocol on Deliriogenic Medication Use in Hospitalized Older Veterans. 谵妄协议对住院老年退伍军人谵妄性药物使用的影响。

Senior Care Pharmacist Pub Date : 2024-08-01 DOI: 10.4140/TCP.n.2024.291

Alison M Weygint, Brandon LaMarr, Stephanie Lee

{"title":"Impact of a Delirium Protocol on Deliriogenic Medication Use in Hospitalized Older Veterans.","authors":"Alison M Weygint, Brandon LaMarr, Stephanie Lee","doi":"10.4140/TCP.n.2024.291","DOIUrl":"10.4140/TCP.n.2024.291","url":null,"abstract":"Background The Southern Arizona VA Health Care System (SAVAHCS) implemented a delirium prevention and treatment protocol in 2019. Objective The primary objective of this study was to determine if the implementation of a delirium protocol influenced deliriogenic medication use in hospitalized geriatric veterans. The secondary objectives were to compare the rates of delirium diagnosis, hospital length-of-stay, and rates of newly started deliriogenic medications during admission pre- and post-protocol. Methods This study was a retrospective, secondary data analysis study. Veterans 65 years of age and older who were admitted to an inpatient medical ward at the SAVAHCS for 24 hours or more between January 1, 2018 and December 31, 2018 (pre-protocol) or January 1, 2021 and December 31, 2021 (post-protocol) were included. Patients were excluded if they had a diagnosis of alcohol or benzodiazepine withdrawal upon admission. Results A total of 5491 patients were included in this study; 2940 (53.5%) in the pre-protocol group and 2551 (46.5%) in the post-protocol group. Patients received at least one deliriogenic medication during their admission in the post-protocol group (36.2%) compared with the pre-protocol group (34.1%), but there was no statistically significant difference (P = 0.098). There were also no significant differences in the rates of documentation of delirium as a diagnosis at discharge, hospital length-of-stay, or the rates of newly started deliriogenic medications during admission between the groups. Conclusion Implementation of a delirium prevention and treatment protocol at the SAVAHCS did not significantly impact the use of deliriogenic medications in hospitalized geriatric veterans.","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"39 8","pages":"291-299"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141856773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MDMA Therapy for PTSD: Inching Closer to-or Farther From-Approval? 治疗创伤后应激障碍的摇头丸疗法：离批准越来越近还是越来越远？

Senior Care Pharmacist Pub Date : 2024-08-01 DOI: 10.4140/TCP.n.2024.311

Leigh Davitian

引用次数: 0

The 2023 American Geriatrics Society Updated Beers Criteria^® Application in Low- and Middle-Income Countries: A Walk-through. 2023 年美国老年医学会更新的 Beers Criteria® 在中低收入国家的应用：走马观花。

Senior Care Pharmacist Pub Date : 2024-08-01 DOI: 10.4140/TCP.n.2024.286

Jehath Syed, Sri Harsha Chalasani

引用次数: 0

Review of Current Clinical Options for the Management of Behavioral and Psychological Symptoms of Dementia. 当前治疗痴呆症行为和心理症状的临床方案回顾。

Senior Care Pharmacist Pub Date : 2024-08-01 DOI: 10.4140/TCP.n.2024.300

Katelyn Malena, Shantanu Rao, Charles Mosler

{"title":"Review of Current Clinical Options for the Management of Behavioral and Psychological Symptoms of Dementia.","authors":"Katelyn Malena, Shantanu Rao, Charles Mosler","doi":"10.4140/TCP.n.2024.300","DOIUrl":"10.4140/TCP.n.2024.300","url":null,"abstract":"Dementia is a disease most prevalent in the older adult population. The cognitive symptoms of dementia include impairments in problem-solving, memory, and language. Some patients experience noncognitive symptoms in addition to the cognitive symptoms of dementia. These noncognitive symptoms are called behavioral and psychological symptoms of dementia or BPSD. The primary objective of our study was to examine the therapeutic options, guidelines, and clinical considerations for the management of BPSD. The existing literature about BPSD was reviewed with searches in PubMed, MEDLINE, and online search platforms. Dysregulation of neurotransmission involving acetylcholine, dopamine, and serotonin has been shown to cause behavioral and psychological symptoms of Alzheimer's disease. BPSD can include hallucinations, agitation, delusions, anxiety, apathy, abnormal body movements, irritability, depression, disinhibition, and sleep or appetite changes. Pharmacologic therapies used in the treatment of BPSD include antidepressants, antipsychotics, anxiolytics, and anticonvulsants. Treatment can be tailored to the specific noncognitive symptoms that are experienced. The use of these agents may be limited based on recommendations from the Beers Criteria®, STOPP criteria, treatment guidelines, and FDA warnings.","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"39 8","pages":"300-310"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141856776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Centers for Medicare & Medicaid Services Tackle Nurse Staffing Rule: Fairy Tale Ending or Endless Litigation? 医疗保险与医疗补助服务中心处理护士配置规则：童话般的结局还是无休止的诉讼？

Senior Care Pharmacist Pub Date : 2024-07-01 DOI: 10.4140/TCP.n.2024.277

Leigh Davitian

引用次数: 0

Unintended Consequences: Consider the Rabbit. 意外后果：考虑兔子

Senior Care Pharmacist Pub Date : 2024-07-01 DOI: 10.4140/TCP.n.2024.238

Chris Alderman

引用次数: 0

Utilization of Lower-Dose Cyclobenzaprine in the Older Inpatient. 低剂量环苯扎林在老年住院患者中的应用。

Senior Care Pharmacist Pub Date : 2024-07-01 DOI: 10.4140/TCP.n.2024.249

Katherine G Coli, Jaylan M Yuksel, Kenneth L McCall, Jiajie Guan, Kelly R Ulen, John Noviasky

{"title":"Utilization of Lower-Dose Cyclobenzaprine in the Older Inpatient.","authors":"Katherine G Coli, Jaylan M Yuksel, Kenneth L McCall, Jiajie Guan, Kelly R Ulen, John Noviasky","doi":"10.4140/TCP.n.2024.249","DOIUrl":"10.4140/TCP.n.2024.249","url":null,"abstract":"Background In older inpatients, anticholinergic medications can increase the risk of complications that may increase length of stay (LOS). Cyclobenzaprine is an anticholinergic medication associated with mental status changes, falls, and injuries in older patients. Objective The purpose of this study is to determine whether use of a lower cyclobenzaprine dose (5 mg) compared with higher dosing (10 mg) will affect LOS, 30-day readmission rates, and need for injectable psychotropic agents in inpatients 65 years of age and older. Methods This was a retrospective cohort analysis comparing outcomes in patients 65 years of age and older who received either a 5 mg or 10 mg cyclobenzaprine dose during their inpatient admission over a 2.5-year period. The primary outcome was hospital LOS, adjusted using multivariate linear regression. Secondary outcomes included 30-day readmission rate adjusted using logistic regression and use of injectable antipsychotics or benzodiazepines. A sub-analysis evaluated the impact of the institution's implementation of a geriatric prescribing context (GEM-CON) on cyclobenzaprine dose selection. Results The adjusted LOS was 32.7% longer (95% CI 25.9%-39.9%) for patients exposed to higher-dose cyclobenzaprine. Use of injectable antipsychotics or benzodiazepines was also significantly greater in the higher-dose group (P < 0.001; P = 0.025). Cyclobenzaprine dose was not significantly associated with readmission on multivariate analysis (OR = 0.93, 95% CI 0.45-1.93). After GEM-CON implementation, there was a significant increase in use of the recommended lower cyclobenzaprine dose (P < 0.001). Conclusion Use of lower cyclobenzaprine dosing in older inpatients is associated with reduced hospital LOS and need for injectable antipsychotics and benzodiazepines.","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"39 7","pages":"249-258"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0